Soleno Therapeutics (SLNO) Non-Current Assets (2013 - 2026)

Soleno Therapeutics (SLNO) has 14 years of Non-Current Assets data on file, last reported at $282.0 million in Q1 2026.

• Non-Current Assets for Q1 2026 came in at $282.0 million, up 2973.03% year-over-year; the trailing twelve-month figure through Mar 2026 was $570.6 million (up 370.02% YoY), and the FY2025 annual result was $208.0 million, up 460.95% from the prior year.
• Non-Current Assets climbed to $282.0 million in Q1 2026 per SLNO's latest filing, from $208.0 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $282.0 million in Q1 2026 and troughed at $9.2 million in Q1 2025.
• A 5-year average of $46.9 million and a median of $12.6 million in 2022 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2025 and 2026: Non-Current Assets slumped 57.64% in 2025, then surged 2973.03% in 2026.
• A 5-year view of Non-Current Assets shows it stood at $10.8 million in 2022, then declined by 13.98% to $9.3 million in 2023, then soared by 297.33% to $37.1 million in 2024, then surged by 460.95% to $208.0 million in 2025, then jumped by 35.57% to $282.0 million in 2026.
• Business Quant data shows SLNO's Non-Current Assets at $282.0 million in Q1 2026, $208.0 million in Q4 2025, and $65.0 million in Q3 2025.